Evidence brief
Selank
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Selank is a peptide with seven amino acids. Small studies in people reported changes in anxiety symptoms. The studies were too limited to prove that Selank treats anxiety or improves focus. No FDA-approved U.S. Selank product was found in the records checked. FDA says important human safety information is missing for the Selank acetate form.
Selank is a seven-amino-acid peptide. Small studies in people do not prove that it treats anxiety or improves focus.
- How strong is the evidence?
- Emerging
Some studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation. - What evidence exists?
- Investigational human outcomes
Studies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed August 30, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as TP-7 · Selanc
Words used here
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
- investigational
- still being studied and not approved for that use
- outcome
- what the study measured
- molecule
- one specific chemical substance
- placebo
- an inactive treatment used for comparison
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- mechanism
- how a substance may cause a body change
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Small studies compared Selank with anxiety medicines. They reported symptom changes. The records reviewed did not include a large repeat study against a placebo.
A 52-person study measured changes in links between brain areas. It did not measure a treatment benefit, focus, memory, or daily function.
Small studies cannot show uncommon or long-term harms. FDA says important human safety information is missing for the Selank acetate form.
The main peptide, a related chemical form, the product used in a study, and products sold as Selank are not automatically the same.
02 · Identity
What it is
Selank is a peptide with seven amino acids. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, also written as TKPRPGP. FDA also lists the names TP-7 and Selanc for this peptide. Selank diacetate is a related chemical form, not another name for every Selank product.
Scientific group: Synthetic neuropeptide. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None found in the U.S. records checked on August 30, 2026.
- Small human studies of anxiety-related conditions
- A human brain-scan study
04 · Research results
What the research shows
One study compared Selank with medazepam in 62 people. A second study compared Selank with phenazepam in 60 people with several anxiety-related conditions. Both reported symptom improvement. Neither cited study summary describes a placebo group, and both summaries gave few details about the methods.
A separate study used brain scans in 52 healthy people who received Selank, Semax, or placebo. It found changes in links between some brain areas. It did not test anxiety treatment, focus, memory, or daily function.
These small studies do not show that Selank is a proven anxiety treatment. They also do not prove better focus, memory, sleep, mood, or daily function. Most reports came from Russian research groups. The reports gave few details about whether people or researchers knew the assigned treatment. They also gave little information about longer follow-up or uncommon harms. No large, independent repeat study was found among the records reviewed.
No FDA-approved U.S. Selank drug was found. FDA says important human safety information is missing for the Selank acetate form. The reviewed records do not show whether an online or compounded product contains the listed chemical form or matches the product used in a study.
Exact product
FDA has separate records for Selank and Selank diacetate, a related chemical form. FDA's compounding page uses the name Selank acetate. These records do not show that a sold or compounded product contains the listed form or matches the product used in a study.
05 · Claim check
Claims I checked
7 claims checked for this brief.
“Selank, Selanc, and TP-7 are names for the same seven-amino-acid peptide.”
Yes. FDA lists Selank, Selanc, and TP-7 as names for one peptide with the sequence TKPRPGP. This record names the substance. It does not show that a related chemical form or sold product is the same.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The Selank peptide in FDA's chemical record. Selank diacetate has a separate related record. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Small studies tested Selank in people with anxiety-related conditions.”
Yes. One randomized report compared Selank with medazepam in 62 people. Another randomized report included 70 people. Forty received Selank with phenazepam, and 30 received phenazepam alone. These small studies do not prove a broad benefit.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Small studies in people with specific anxiety-related conditions. The reports do not establish a result for every anxiety condition or population. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Selank is a proven treatment for anxiety.”
The studies were small and compared Selank with another medicine. The reports did not clearly say whether people and researchers knew the assigned treatment. No large, repeated result against a placebo was found.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- A reliable treatment conclusion for anxiety disorders across people, settings, and products. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
Show 4 more claim checks
“Selank improves focus, memory, or daily function.”
A 52-person study measured links between brain areas. It did not test focus, memory, or daily function. An earlier report mentioned a possible effect on thinking, but its study summary gave no clear result for these outcomes.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Focus, memory, and daily-function outcomes in people who received a verified Selank study product. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Selank is FDA-approved in the United States.”
No FDA-approved U.S. Selank product was found in the records checked. FDA's chemical record names the substance. It does not approve a drug. The request to add Selank acetate to a compounding list was withdrawn. That request was not approval.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- United States drug-approval and compounding records checked on August 30, 2026. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Selank, Selank diacetate, and every product sold as Selank are interchangeable.”
FDA has separate records for the main peptide and Selank diacetate, a related chemical form. A product name does not prove what it contains, its quality, or whether it matches the product used in a study.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The peptide, its related chemical form, and each finished or compounded product must be checked separately. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Selank has a proven safety profile in people.”
The human studies were small and cannot show uncommon or long-term harms. FDA says important human safety information is missing for Selank acetate. For some ways of using it, FDA also warns of possible immune reactions from peptide clumps or related impurities.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Long-term safety, uncommon harms, and the safety of each way it is used, chemical form, and finished product. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Selank
No. FDA lists Selank and Selank diacetate as different chemical forms. A product name does not prove which form it contains or whether it matches the product used in a study.
No FDA-approved U.S. Selank product was found in the records checked. FDA's chemical record names the substance. It does not approve a drug. The request to add Selank acetate to a compounding list was withdrawn. That request was not approval.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
One study compared Selank with medazepam in 62 people. A second study compared Selank with phenazepam in 60 people with several anxiety-related conditions. Both reported symptom improvement. Neither cited study summary describes a placebo group, and both summaries gave few details about the methods. A separate study used brain scans in 52 healthy people who received Selank, Semax, or placebo. It found changes in links between some brain areas. It did not test anxiety treatment, focus, memory, or daily function.
These small studies do not show that Selank is a proven anxiety treatment. They also do not prove better focus, memory, sleep, mood, or daily function. Most reports came from Russian research groups. The reports gave few details about whether people or researchers knew the assigned treatment. They also gave little information about longer follow-up or uncommon harms. No large, independent repeat study was found among the records reviewed. No FDA-approved U.S. Selank drug was found. FDA says important human safety information is missing for the Selank acetate form. The reviewed records do not show whether an online or compounded product contains the listed chemical form or matches the product used in a study.
07 · Safety
Safety limits for this record
FDA warns of possible immune reactions with some ways of using compounded Selank acetate. Peptide clumps or related impurities could cause the reaction. FDA also says important human safety information is missing for this chemical form. Short studies cannot show uncommon or long-term harms. This guide gives no dosing, spray, injection, buying, sourcing, or treatment advice.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief reviewed FDA identity, approval, and compounding records, three small anxiety studies, and a human brain-scan study.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.